Trials / Recruiting
RecruitingNCT06689163
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
An Open, Multicenter Phase Ib/II Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-1167 tablets | HRS-1167 tablets |
| DRUG | Abiraterone Acetate tablets（II） | Abiraterone Acetate tablets（II） |
| DRUG | Prednisone Acetate tablets | Prednisone Acetate tablets |
Timeline
- Start date
- 2024-12-11
- Primary completion
- 2025-11-30
- Completion
- 2026-12-31
- First posted
- 2024-11-14
- Last updated
- 2025-09-03
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06689163. Inclusion in this directory is not an endorsement.